These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24063899)

  • 1. [Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
    Tural C; Planas R
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():19-25. PubMed ID: 24063899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Macías J; Rivero A
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Telaprevir in HCV-monoinfected patients with failure to prior treatment].
    Solà R; Forns X
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():14-8. PubMed ID: 24063898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in hepatitis C treatment].
    Vinaixa C; Aguilera V; Berenguer M
    Med Clin (Barc); 2013 Nov; 141(10):447-52. PubMed ID: 23601737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Telaprevir in treatment-naïve patients with HCV monoinfection].
    Cabezas J; Crespo J; Selmo J; Luis Calleja J
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():7-13. PubMed ID: 24063897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
    Albillos A; Luis Calleja J; Molina E; Planas R; Romero-Gómez M; Turnes J; Hernández-Guerra M
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():13-22. PubMed ID: 25907434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Yamada A; Oshita M; Kaneko A; Suzuki K; Inui Y; Tamura S; Yoshihara H; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2015 Mar; 50(3):313-22. PubMed ID: 24806033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
    Crespo J; Berenguer M; Pérez F; Fernández I; González O; Bárcena R; Buti M; López J; Calleja JL;
    Gastroenterol Hepatol; 2015 Nov; 38(9):517-24. PubMed ID: 25976446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].
    Bruguera M; Esteban R; Forns X; Planas R; Quer JC; Solà R; Vergara M;
    Gastroenterol Hepatol; 2012 Nov; 35(9):667-74. PubMed ID: 22560187
    [No Abstract]   [Full Text] [Related]  

  • 19. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
    Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
    Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.